References

IgA nephropathy.

10.1038/s41572-023-00476-9 · 2023 · External reference

Executive summary of the KDIGO 2025 clinical practice guideline for the management of immunoglobulin a nephropathy (IgAN) and immunoglobulin a vasculitis (IgAV).

10.1016/j.kint.2025.04.003 · 2025 · External reference

Aberrantly glycosylated IgA1 in IgA nephropathy: what we know and what we don’t know.

10.3390/jcm10163467 · 2021 · External reference

Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis.

10.1016/j.kint.2025.07.038 · 2025 · External reference

Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis.

10.3389/fimmu.2023.1209394 · 2023 · External reference

Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis.

10.1007/s40620-023-01874-8 · 2024 · External reference

The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression.

10.1038/ki.2012.197 · 2012 · External reference

Correlation of serum galactose-deficient IgA1 and Oxford class in cases of IgA nephropathy.

10.5858/arpa.2023-0190-oa · 2024 · External reference

Absence of glomerular IgA1 deposition despite overexpression of galactose-deficient IgA1 in the B cell c1galt1 knockout mouse.

10.1016/j.kint.2026.02.034 · 2026 · External reference

Results from part a of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin a nephropathy.

10.1016/j.kint.2022.09.017 · 2023 · External reference

Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin a nephropathy: insights from the NEFIGAN trial.

10.1016/j.kint.2023.11.003 · 2024 · External reference

Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy.

10.1016/j.ekir.2024.01.003 · 2024 · External reference

Telitacicept for IgA nephropathy - interim analysis of a phase 3 Trial.

10.1056/nejmoa2514415 · 2026 · External reference

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.

10.1016/j.kint.2024.03.012 · 2024 · External reference

Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy.

10.1681/asn.0000000541 · 2025 · External reference

Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy.

10.1016/j.kint.2025.05.006 · 2025 · External reference

IgA nephropathy: the lectin pathway and implications for targeted therapy.

10.1016/j.kint.2023.04.029 · 2023 · External reference

Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group.

10.1016/j.kint.2017.02.003 · 2017 · External reference

Galactose-deficient IgA1 B cells in the circulation of iga nephropathy patients carry preferentially lambda light chains and mucosal homing receptors.

10.1681/asn.2021081086 · 2022 · External reference

Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+β7+ cells in IgA nephropathy.

10.1016/j.kint.2025.12.026 · 2026 · External reference

Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy.

10.1016/j.kint.2021.04.026 · 2021 · External reference

IgA nephropathy: gut microbiome regulates the production of hypoglycosilated IgA1 via the TLR4 signaling pathway.

10.1093/ndt/gfae052 · 2024 · External reference

TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.

10.1016/j.kint.2019.08.022 · 2020 · External reference

Aberrant IgA1 glycosylation in IgA nephropathy: a systematic review.

10.1371/journal.pone.0166700 · 2016 · External reference

O- and N-Glycosylation of serum immunoglobulin a is associated with IgA nephropathy and glomerular function.

10.1681/asn.2020081208 · 2021 · External reference

Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy.

10.1038/s41467-025-60819-w · 2025 · External reference

Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.

10.1038/ki.2015.158 · 2015 · External reference

Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide.

10.1093/ckj/sfaf203 · 2025 · External reference

Poly-IgA immune complex as a monitoring biomarker of response to telitacicept in IgA nephropathy.

10.3389/fimmu.2026.1751549 · 2026 · External reference

Mesangial C3 deposition, complement-associated variant, and disease progression in IgA nephropathy.

10.2215/cjn.0000000000000290 · 2023 · External reference

Urinary complement biomarkers in immune-mediated kidney diseases.

10.3389/fimmu.2024.1357869 · 2024 · External reference

Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy.

10.1016/j.ekir.2020.08.003 · 2020 · External reference

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin a Nephropathy (ARTEMIS-IgAN).

2026 · External reference

Urinary IL-18 predicts progression of IgA nephropathy.

10.1186/s12882-026-04965-3 · 2026 · External reference

The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies.

10.3389/fneph.2023.1346769 · 2024 · External reference

New insights and future perspectives of APRIL in IgA Nephropathy.

10.3390/ijms251910340 · 2024 · External reference

A Phase 3 Trial of atacicept in patients with IgA nephropathy.

10.1056/nejmoa2510198 · 2026 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Incidence of latent mesangial IgA deposition in renal allograft donors in Japan.

10.1046/j.1523-1755.63.6s.2.x · 2003 · External reference

Immune characteristics of renal allograft donors with mesangial IgA deposition.

10.1016/j.intimp.2020.107282 · 2021 · External reference

Evaluating a new international risk-prediction tool in IgA nephropathy.

10.1001/jamainternmed.2019.0600 · 2019 · External reference